deltatrials
Terminated PHASE3 INTERVENTIONAL 1-arm NCT03447262

A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy

A Phase 3, Open-label Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation

Sponsor: Vertex Pharmaceuticals Incorporated

Conditions Cystic Fibrosis
Interventions IVA VX-659/TEZ/IVA
Updated 14 times since 2018 Last updated: Dec 31, 2021 Started: Jul 13, 2018 Primary completion: Sep 9, 2020 Completion: Sep 9, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

At Sponsor's Discretion

Other terminated trials from Vertex Pharmaceuticals Incorporated

See all terminations from Vertex Pharmaceuticals Incorporated

Other Cystic Fibrosis trials with similar outcome

Browse all Cystic Fibrosis trials

A PHASE3 clinical study on Cystic Fibrosis, this trial is terminated or withdrawn. The trial is conducted by Vertex Pharmaceuticals Incorporated and has accumulated 14 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Mar 2018 – ~Aug 2018 · 5 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Feb 2019 · 4 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Apr 2020 · 12 months · monthly snapshot~Apr 2020 – ~Nov 2020 · 7 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2022 · 13 months · monthly snapshot~Feb 2022 – ~Jul 2024 · 29 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Feb 2022 — Jul 2024 [monthly]

    Terminated PHASE3

    Status: Completed → Terminated

  5. Jan 2021 — Feb 2022 [monthly]

    Completed PHASE3

▶ Show 9 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Apr 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

  3. Apr 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Enrolling By Invitation → Active Not Recruiting

  4. Mar 2019 — Apr 2019 [monthly]

    Enrolling By Invitation PHASE3

  5. Feb 2019 — Mar 2019 [monthly]

    Enrolling By Invitation PHASE3

  6. Oct 2018 — Feb 2019 [monthly]

    Enrolling By Invitation PHASE3

  7. Sep 2018 — Oct 2018 [monthly]

    Enrolling By Invitation PHASE3

  8. Aug 2018 — Sep 2018 [monthly]

    Enrolling By Invitation PHASE3

    Status: Not Yet Recruiting → Enrolling By Invitation

  9. Mar 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Vertex Pharmaceuticals Incorporated
Data source: Vertex Pharmaceuticals Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Albany, United States , Ann Arbor, United States , Aurora, United States , Baltimore, United States , Barcelona, Spain , Berlin, Germany , Bern, Switzerland , Birmingham, United States , Boise, United States and 82 more locations